Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol

NCT00531050 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Indacaterol
DRUG: Placebo
DRUG: Salmeterol

Sponsor

Novartis